This episode, titled, ‘Clinical and Biomarker Signals for Escalating Therapy in High-Risk CKD,’ features panelists discussing the following critical question:

What clinical or biomarker-based signals prompt treatment modifications or escalations in patients with CKD and elevated cardiovascular risk?

Led by the moderator, this discussion explores how clinicians can use "responsive" biomarkers to combat the "silent" nature of early-stage CKD and keep patients engaged in their care. Much like HbA1c in diabetes or LDL-C in lipid management, the panel suggests that tracking uACR provides a visual feedback loop that proves a drug is working, specifically aiming for the ADA-recommended 30% reduction. Dr. Desai and Dr. Kushner explain that this feedback is essential for shared decision-making, allowing clinicians to tailor the "starting therapy" based on a patient’s unique profile—such as prioritizing GLP-1 receptor agonists for a patient with obesity or SGLT2 inhibitors for those with heart failure with reduced ejection fraction (HFrEF).

The experts also contrast the "race to four drugs" seen in heart failure with the longer-term horizon of CKD, suggesting that while the ultimate goal remains comprehensive cardiorenal protection, the sequencing of medications can be a collaborative, incremental process. By framing uACR reduction as an improvement in systemic endothelial health and a decrease in cardiovascular risk (as reflected in updated PREVENT scores), clinicians can move from a "one-size-fits-all" recipe to a nuanced, patient-centered strategy. This approach is particularly effective for patients with a family history of dialysis, where the motivation to intercept disease progression is high, making the "fun part" of clinical practice the integration of evidence-based guidelines with personalized patient goals.

In the last episode, ‘Optimizing Multidisciplinary Collaboration in CKD Management,’ the panelists advocate for transforming the CKM care pathway by leveraging electronic health records (EHR) as a universal platform for trust and communication among primary care and specialist teams. They emphasize a multidisciplinary "team-based" approach—utilizing pharmacists for titration and telehealth for monitoring—to ensure that the momentum of early diagnosis is maintained throughout the long-term journey of chronic disease management.